Celemics, Inc. Logo

Celemics, Inc.

Develops custom NGS panels and bioinformatics for research and clinical diagnostics.

331920 | KO

Overview

Corporate Details

ISIN(s):
KR7331920009
LEI:
Country:
South Korea
Address:
서울특별시 금천구 가산디지털1로 131, A동 19층 및 20층 2004호 외, 금천구
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Celemics, Inc. is a biotechnology company specializing in Next-Generation Sequencing (NGS) solutions for research and clinical diagnostics. The company develops and manufactures a comprehensive portfolio of products, including hybridization-based NGS target enrichment panels, whole exome sequencing (WES) kits, library preparation kits, and bioinformatics analysis services. Utilizing proprietary technologies in probe design, molecular barcoding, and bioinformatics, Celemics provides both ready-to-use and fully customized panels tailored for various applications. Its key markets include oncology, liquid biopsy, biopharma, inherited disease analysis, pharmacogenomics, pathogen detection, and agrigenomics, offering end-to-end solutions from assay development to data analysis.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-13 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.2 MB
2025-05-19 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.8 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.3 MB
2025-03-27 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 24.8 KB
2025-03-27 00:00
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 10.2 KB
2025-03-19 00:00
Audit Report / Information
감사보고서제출
Korean 25.1 KB
2025-03-19 00:00
Audit Report / Information
사업보고서 (2024.12)
Korean 430.2 KB
2025-03-19 00:00
Annual Report
[기재정정]사업보고서 (2024.12)
Korean 1.5 MB
2025-03-04 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 11.8 KB
2025-03-04 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 158.7 KB
2025-03-04 00:00
Pre-Annual General Meeting Information
주주총회집중일개최사유신고
Korean 4.3 KB
2025-03-04 00:00
Proxy Solicitation & Information Statement
의결권대리행사권유참고서류
Korean 159.1 KB
2025-02-19 00:00
Earnings Release
매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 10.9 KB
2024-12-17 00:00
Regulatory News Service
단일판매ㆍ공급계약체결
Korean 9.6 KB
2024-11-14 00:00
Quarterly Report
분기보고서 (2024.09)
Korean 1.1 MB

Automate Your Workflow. Get a real-time feed of all Celemics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Celemics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Celemics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Tourmaline Bio, Inc. Logo
Develops an anti-IL-6 antibody for cardiovascular, inflammatory, and immune diseases.
United States of America
TRML
TOWA PHARMACEUTICAL CO.,LTD. Logo
Manufactures and markets high-quality, accessible generic drugs for various therapeutic areas.
Japan
4553
Transcode Therapeutics, Inc. Logo
Develops targeted RNA therapies for metastatic cancer using a proprietary nanoparticle delivery platform.
United States of America
RNAZ
Travere Therapeutics, Inc. Logo
Develops therapies for rare kidney and metabolic diseases, with an FDA-approved treatment for IgA nephropathy.
United States of America
TVTX
Traws Pharma, Inc. Logo
Develops oral small-molecule therapies for respiratory viral diseases and cancer.
United States of America
TRAW
TScan Therapeutics, Inc. Logo
Developing TCR-engineered T-cell therapies for solid and hematologic cancers.
United States of America
TCRX
TSUMURA & CO. Logo
A leader in Japanese Kampo herbal medicine, producing prescription and OTC formulations.
Japan
4540
TuHURA Biosciences, Inc./NV Logo
Phase 3 immuno-oncology firm developing therapeutics to overcome cancer therapy resistance.
United States of America
HURA
TURK İLAÇ VE SERUM SANAYİ A.Ş. Logo
Turkish producer of pharmaceuticals, specializing in IV solutions and vaccines for hospitals.
Türkiye
TRILC
Tvardi Therapeutics, Inc. Logo
Developing oral STAT3 inhibitors to treat cancers and fibrosis-driven diseases.
United States of America
TVRD

Talk to a Data Expert

Have a question? We'll get back to you promptly.